The invention relates to a method of customizing a nail-biting and/or finger sucking treatment solution, and a kit for providing a nail-biting and finger sucking treatment that is customizable for a wide range of afflicted users seeking to break a persistent nail-biting and/or finger sucking habit. In exemplary embodiments, the composition kit includes two separate containers, a first container having a nail growth-promoting, waterproofing composition that may be applied directly on a user's nails; and a second container may include an additive for customizing a bitterness factor of the first composition. Typically, the first container includes an applicator such as a brush. To facilitate adding the additive in a manner that is easily customizable, the second container may include a dropper for adding small doses of the additive composition to the first composition. The customizable kit allows the user to safely adjust the bitterness so that the treatment remains effective.

The invention generally relates to keto ester compositions and methods for using the compositions. In one aspect, the invention provides a method for preventing a metabolic-related condition or disorder in a subject, the method comprising the step of providing to the subject an effective amount of at least one keto ester compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one maltodextrin compound, thereby preventing the metabolic-related condition or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention generally relates to keto ester compositions and methods for using the compositions. In one aspect, the invention provides a method for preventing a metabolic-related condition or disorder in a subject, the method comprising the step of providing to the subject an effective amount of at least one keto ester compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one maltodextrin compound, thereby preventing the metabolic-related condition or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.

The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.

The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.

The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the preparation of these nitric oxide releasing prodrugs, to pharmaceutical compositions containing them and to methods of using these produgs.

The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the preparation of these nitric oxide releasing prodrugs, to pharmaceutical compositions containing them and to methods of using these produgs.

The present invention relates to waxes useful for cosmetic applications having stable oil-in-water emulsion-forming properties and, in some embodiments, stable gel-in-water-forming properties. In some embodiments, the waxes exhibit self-emulsifying properties, and can be produced without the addition of any other substances to achieve the emulsion (e.g., co-emulsifiers, hydrophilic polymers, polar surfactants, rheological modifiers, gelling agents). The waxes generally comprise: (a) polyglyceryl fatty acid ester, (b) a glycerol fatty acid ester, and 9c) a fatty alcohol. In particular embodiments, the polyglyceryl fatty acid ester can be a polyglyceryl-2, -3, or -4 fatty acid ester, and the fatty chain lengths of (a)-(c) can range from C12 to C22. In more particular embodiments, the waxes can comprise polyglyceryl stearate, glyceryl stearate, and stearyl alcohol. Gels, oil-in-water emulsions, and other compositions produced from the waxes, as well as uses and methods relating thereto, are also disclosed.

The present invention provides an inhalation-type pharmaceutical composition for gout and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising colchicine, allopurinol, probenecid, sulfinpyrazone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.